Current status and future perspectives of dendritic cell-based cancer immunotherapy

Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer

Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome

Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer

Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine.